Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Mid, smallcap stocks biggest losers
Fri, 25 Jul 01:30 pm

Indian stock markets continued its southward journey below the dotted line during the previous two hours of trade led by heavy selling activity across sectors. Selling pressure is led by stocks from realty and power sectors, whereas healthcare and FMCG stocks are trading firm.

The BSE-Sensex is trading down 207 points and the NSE-Nifty is trading down 67 points. The BSE Mid Cap index is trading down 1.8% and the BSE Small Cap index is trading down 2.4% today. The rupee is trading at 60.14 to the US dollar.

Food & tobacco stocks are trading on a mixed note today. While GSK Consumers is leading the pack of a few gainers, Tata Global Beverages and Ruchi Soya are trading weak. As per a leading business daily, FMCG major ITC plans to lay greater emphasis in supplying its FMCG products directly to retailers in a move to revitalize its distribution strategy. As such, the company targets to reach out to 1 lakh villages that accounts for 80% of India's rural consumer goods consumption. This will enable ITC to directly reach out to retailers bypassing wholesalers and stockists. The company's rural push matches the scale of market leader HUL, which launched an initiative of Perfect Village last year and covered 8,500 villages. It may be noted that ITC has been focusing on the consumer good segment in line with the company chairman's vision to turm the company in to the nation's largest FMCG company. As such, its FMCG business broke even during FY14. ITC is trading higher by 0.2%

Majority of the domestic pharma stocks are trading in the green led by Sun Pharma and J B Chemicals whereas Panacea Biotech and Piramal Enterprises are among major losers. As per a leading financial daily, Ranbaxy Laboratories has signed a licensing agreement with Cipher Pharmaceuticals for exclusive marketing, selling and distributing the latter's isotretinoin capsules in Brazil. Ranbaxy is already distributing Cipher's isotretinoin product in United States under the brand Absorica. Isotretinoin is used in the treatment of severe recalcitrant nodular acne. Ranbaxy will be responsible for obtaining regulatory approval for the product in Brazil which will be promoted through a brand dermatology division. As per the terms of the agreement, Cipher will receive an upfront payment as well as pre-commercial milestone payments. Ranbaxy stock is currently trading up by 2.4%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Mid, smallcap stocks biggest losers". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.